Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PLA2G4B | P0C869 | 8/20 | 0.97 |
| ▸ | RARB | P10826 | 4/20 | 0.90 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.70 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10778285 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL371494 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL503568 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL10777726 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL3625733 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1163918 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1322922 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL7470745 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL503352 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL503367 | 1.00 | TP53 (1.00) | TP53TSHRPLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216649-B2 | Liquid crystal aligning agent, method of producing a liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2012-07-10 | — | — | US | claimed |
| WO-2026099001-A1 | ADDITIVE COMPOSITION FOR POWDER COATINGS | EVONIK OPERATIONS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| EP-3710462-B1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LTD (NZ) | 2026-05-13 | — | — | EP | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-11510980-B2 | Brartemicin analogues | VICTORIA LINK LTD. (NZ) | 2022-11-29 | — | — | US | disclosed |
| CN-111234208-B | Polyester/polyamide copolymer and preparation method and application thereof | 中山大学 | 2021-07-16 | — | — | CN | disclosed |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2021-06-17 | — | — | US | disclosed |
| EP-3710462-A1 | BRARTEMICIN ANALOGUES | Victoria Link Limited (NZ) | 2020-09-23 | — | — | EP | disclosed |
| US-5424183-A | Stable color images, high resolution | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-06-13 | — | — | US | disclosed |
| US-5395815-A | Phenolic compound electron acceptor; images; contrast; stability | MITSUBISHI PAPER MILLS LIMITED (JP) | 1995-03-07 | — | — | US | disclosed |
| WO-1994022055-A1 | BALLASTED LEUCO DYES AND PHOTOTHERMOGRAPHIC ELEMENT CONTAINING SAME | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0574879-A1 | Reversible heat-sensitive recording material | MITSUBISHI PAPER MILLS, LTD. (JP) | 1993-12-22 | — | — | EP | disclosed |
| EP-0188222-B1 | NOVEL LIQUID CRISTALLINE COMPOUNDS HAVING SUBSTITUENTS | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-04-29 | — | — | EP | disclosed |
| EP-0208617-B1 | CONTROLLED DRUG DEVICE AND PROCESS FOR CATALYSING THE EROSION OF AN ACID LABILE POLYMER | MERCK & CO. INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4943386-A | FERROELECTRIC, GOOD RESPONSE AND MEMORY | DAINIPPON INK & CHEMICALS, INC. (JP) | 1990-07-24 | — | — | US | disclosed |
| US-4828754-A | TILT-TYPE CHIRAL SMECTIC PHASE | DAINIPPON INK & CHEMICALS, INC. (JP) | 1989-05-09 | — | — | US | disclosed |
| EP-0208617-A1 | Controlled drug device and process for catalysing the erosion of an acid labile polymer | MERCK & CO. INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| EP-0188222-A2 | Novel liquid cristalline compounds having substituents | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | TP53 4718/4885TSHR 2176/4885PLA2G4B 1155/4885 |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A9, SLC6A5, REN | TP53 4795/4885TSHR 4030/4885PLA2G4B 2926/4885 |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, CMKLR1 | TP53 4710/4885TSHR 1964/4885PLA2G4B 988/4885 |
| US-11510980-B2 | Brartemicin analogues | RXFP1, RXFP2, CMKLR1 | TP53 4710/4885TSHR 1964/4885PLA2G4B 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.